Seeking Alpha
06 Aug 2026, 12:44 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Sibeprenlimab demonstrated a statistically significant preservation of eGFR compared to placebo over 24 months in the Phase III VISIONARY study for IgA Nephropathy. — Positive Phase III results for a primary endpoint are a critical catalyst for FDA approval and future commercial revenue.
+0.80The drug showed a favorable safety and tolerability profile across the 24-month treatment period. — Safety data reduces the risk of regulatory rejection or black-box warnings, supporting the overall valuation of the asset.
+0.40Which stocks this story touches
The company is reporting long-term eGFR results from a Phase III study for its drug Sibeprenlimab, indicating clinical progress.
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
2h ago
